Cargando…

Biomarkers and recent advances in the management and therapy of sickle cell disease

Although production of hemoglobin S, the genetic defect that causes sickle cell disease (SCD), directly affects only red blood cells, the manifestations of SCD are pervasive, and almost every cell type and organ system in the body can be involved. Today, the vast majority of patients with SCD who re...

Descripción completa

Detalles Bibliográficos
Autor principal: Telen, Marilyn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963010/
https://www.ncbi.nlm.nih.gov/pubmed/27508053
http://dx.doi.org/10.12688/f1000research.6615.1
_version_ 1782444896586563584
author Telen, Marilyn J.
author_facet Telen, Marilyn J.
author_sort Telen, Marilyn J.
collection PubMed
description Although production of hemoglobin S, the genetic defect that causes sickle cell disease (SCD), directly affects only red blood cells, the manifestations of SCD are pervasive, and almost every cell type and organ system in the body can be involved. Today, the vast majority of patients with SCD who receive modern health care reach adulthood thanks to vaccine prophylaxis and improvements in supportive care, including transfusion. However, once patients reach adulthood, they commonly experience recurrent painful vaso-occlusive crises and frequently have widespread end-organ damage and severely shortened life expectancies. Over the last several decades, research has elucidated many of the mechanisms whereby abnormal red blood cells produce such ubiquitous organ damage. With these discoveries have come new ways to measure disease activity. In addition, new pharmaceutical interventions are now being developed to address what has been learned about disease mechanisms.
format Online
Article
Text
id pubmed-4963010
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-49630102016-08-08 Biomarkers and recent advances in the management and therapy of sickle cell disease Telen, Marilyn J. F1000Res Review Although production of hemoglobin S, the genetic defect that causes sickle cell disease (SCD), directly affects only red blood cells, the manifestations of SCD are pervasive, and almost every cell type and organ system in the body can be involved. Today, the vast majority of patients with SCD who receive modern health care reach adulthood thanks to vaccine prophylaxis and improvements in supportive care, including transfusion. However, once patients reach adulthood, they commonly experience recurrent painful vaso-occlusive crises and frequently have widespread end-organ damage and severely shortened life expectancies. Over the last several decades, research has elucidated many of the mechanisms whereby abnormal red blood cells produce such ubiquitous organ damage. With these discoveries have come new ways to measure disease activity. In addition, new pharmaceutical interventions are now being developed to address what has been learned about disease mechanisms. F1000Research 2015-10-12 /pmc/articles/PMC4963010/ /pubmed/27508053 http://dx.doi.org/10.12688/f1000research.6615.1 Text en Copyright: © 2015 Telen MJ http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Telen, Marilyn J.
Biomarkers and recent advances in the management and therapy of sickle cell disease
title Biomarkers and recent advances in the management and therapy of sickle cell disease
title_full Biomarkers and recent advances in the management and therapy of sickle cell disease
title_fullStr Biomarkers and recent advances in the management and therapy of sickle cell disease
title_full_unstemmed Biomarkers and recent advances in the management and therapy of sickle cell disease
title_short Biomarkers and recent advances in the management and therapy of sickle cell disease
title_sort biomarkers and recent advances in the management and therapy of sickle cell disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963010/
https://www.ncbi.nlm.nih.gov/pubmed/27508053
http://dx.doi.org/10.12688/f1000research.6615.1
work_keys_str_mv AT telenmarilynj biomarkersandrecentadvancesinthemanagementandtherapyofsicklecelldisease